Ravi Singh
Ravi Singh has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Sushil Kumar Singh
Pharmaceutical Chemistry Research Laboratory I, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India
9 shared publications - Ashok Kumar
Pharmaceutical Chemistry Research Laboratory 1, Department of Pharmaceutical Engineering & Technology Indian Institute of Technology (Banaras Hindu University) Varanasi India
7 shared publications - Ankit Ganeshpurkar
Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University)
6 shared publications - Powsali Ghosh
Pharmaceutical Chemistry Research Laboratory 1, Department of Pharmaceutical Engineering & Technology Indian Institute of Technology (Banaras Hindu University) Varanasi India
6 shared publications Devendra Kumar
Faculty of Pharmacy, DIT University
5 shared publicationsAnkit Vyankatrao Pokle
Department of Pharmaceutical Engineering & Technology, Pharmaceutical Chemistry Research Laboratory 1, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
2 shared publications
Latest Publications
- 13 December 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (4) , 1887-1901
Integrated application of target-based and ligand-based drug-designing approaches for the identification of novel caspase-6 inhibitors
Caspase-6 (CASP6) is an effector caspase that has been marked to possess various pathological attributes associated with neurodegeneration. It is widely expressed in the neurodegenerative brain and peripheral tissues. It plays a vital role in apoptotic cell death and also performs non-apoptotic functions like axon pruning which contribute to the degeneration of neurons. Increment in active CASP6 levels in the cerebrospinal fluid has been observed during inflammation and has been linked to the early onset of Alzheimer's disease (AD). In the current study, a novel CASP6 inhibitor was identified with the help of integrated target-based and ligand-based drug-designing approaches. Various molecular features of US9 (PDB ID 8EG6) were used to generate models. The pharmacophore models were evaluated using the EF value, GH score, and percentage yield to select the best-suited model. The best model was used to screen the ZINC-15 database to obtain virtual hits. The undesirable compounds were eliminated using various nodes in KNIME workflow. The resulting compounds were further subjected to docking-based virtual screening (DBVS) to find the lead compounds. Further, the molecular docking studies were carried out in three stages, followed by pharmacokinetic property prediction and toxicity studies. The top two virtual hits, i.e. ZINC000012563650 and ZINC000069415222, were considered for molecular dynamics simulation studies. Compound ZINC000069415222 was found to possess better stability, drug-like properties, and lower toxicity under simulated conditions. Thus, ZINC000069415222 was identified as a potential CASP6 inhibitor that could be further explored experimentally as an anti-AD drug.
- 13 December 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (4) , 1887-1901
Integrated application of target-based and ligand-based drug-designing approaches for the identification of novel caspase-6 inhibitors
Caspase-6 (CASP6) is an effector caspase that has been marked to possess various pathological attributes associated with neurodegeneration. It is widely expressed in the neurodegenerative brain and peripheral tissues. It plays a vital role in apoptotic cell death and also performs non-apoptotic functions like axon pruning which contribute to the degeneration of neurons. Increment in active CASP6 levels in the cerebrospinal fluid has been observed during inflammation and has been linked to the early onset of Alzheimer's disease (AD). In the current study, a novel CASP6 inhibitor was identified with the help of integrated target-based and ligand-based drug-designing approaches. Various molecular features of US9 (PDB ID 8EG6) were used to generate models. The pharmacophore models were evaluated using the EF value, GH score, and percentage yield to select the best-suited model. The best model was used to screen the ZINC-15 database to obtain virtual hits. The undesirable compounds were eliminated using various nodes in KNIME workflow. The resulting compounds were further subjected to docking-based virtual screening (DBVS) to find the lead compounds. Further, the molecular docking studies were carried out in three stages, followed by pharmacokinetic property prediction and toxicity studies. The top two virtual hits, i.e. ZINC000012563650 and ZINC000069415222, were considered for molecular dynamics simulation studies. Compound ZINC000069415222 was found to possess better stability, drug-like properties, and lower toxicity under simulated conditions. Thus, ZINC000069415222 was identified as a potential CASP6 inhibitor that could be further explored experimentally as an anti-AD drug.
- 20 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (5) , 2187-2203
Computational screening of coumarin derivatives as inhibitors of the NACHT domain of NLRP3 inflammasome for the treatment of Alzheimer’s disease
The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR), leucine-rich-repeat (LRR), and pyrin domain containing 3 (NLRP3) is one of the key players in neuroinflammation, which is a major pathological hallmark of Alzheimer's Disease (AD). Activated NLRP3 causes release of pro-inflammatory molecules that aggravate neurodegeneration. Thus, pharmacologically inhibiting the NLRP3 inflammasome has the potential to alleviate the inflammatory injury to the neurons. Coumarin is a multifunctional nucleus with potent anti-inflammatory properties and can be utilized to develop novel drugs for the treatment and management of AD. In the present study, we have explored the NLRP3-inhibitory activities of a library of coumarin derivatives through a computational drug discovery approach. Drug-like, PAINS free, and potentially BBB permeable compounds were screened out and subjected to molecular docking and in silico ADMET studies, resulting in three virtual hits, i.e. MolPort-050-872-358, MolPort-050-884-068, and MolPort-051-135-630. The hits exhibited better NLRP3-binding affinity than MCC950, a selective inhibitor of NLRP3. Further, molecular dynamics (MD) simulations, post-MD simulation analyses, and binding free energy calculations of the hits established their potential as promising virtual leads with a common coumarin scaffold for the inhibition of NLRP3 inflammasome.Communicated by Ramaswamy H. Sarma.
- 20 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (5) , 2187-2203
Computational screening of coumarin derivatives as inhibitors of the NACHT domain of NLRP3 inflammasome for the treatment of Alzheimer’s disease
The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR), leucine-rich-repeat (LRR), and pyrin domain containing 3 (NLRP3) is one of the key players in neuroinflammation, which is a major pathological hallmark of Alzheimer's Disease (AD). Activated NLRP3 causes release of pro-inflammatory molecules that aggravate neurodegeneration. Thus, pharmacologically inhibiting the NLRP3 inflammasome has the potential to alleviate the inflammatory injury to the neurons. Coumarin is a multifunctional nucleus with potent anti-inflammatory properties and can be utilized to develop novel drugs for the treatment and management of AD. In the present study, we have explored the NLRP3-inhibitory activities of a library of coumarin derivatives through a computational drug discovery approach. Drug-like, PAINS free, and potentially BBB permeable compounds were screened out and subjected to molecular docking and in silico ADMET studies, resulting in three virtual hits, i.e. MolPort-050-872-358, MolPort-050-884-068, and MolPort-051-135-630. The hits exhibited better NLRP3-binding affinity than MCC950, a selective inhibitor of NLRP3. Further, molecular dynamics (MD) simulations, post-MD simulation analyses, and binding free energy calculations of the hits established their potential as promising virtual leads with a common coumarin scaffold for the inhibition of NLRP3 inflammasome.Communicated by Ramaswamy H. Sarma.
- 12 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (9) , 4679-4698
Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach
Histone deacetylase 2 (HDAC2) is associated with various neuropathic degenerative diseases and is considered a novel target for Alzheimer's disease (AD). Elevated levels of HDAC2 trigger excitatory neurotransmission and reduce synaptic plasticity, synaptic number, and memory formation. In the current study, we identified HDAC2 inhibitors using an integrated structure and ligand-based approaches to drug design. Three pharmacophore models were generated by using different pharmacophoric features and validated using the Enrichment factor (EF), Guner-henry (GH) score, and percentage yield. The model of choice was used to screen a library of Zinc-15 compounds and interfering compounds were eliminated by using drug likeliness and PAINS filtering. Further, docking studies in three stages were carried out to obtain hits with good binding energies and were followed by ADMET studies yielding three virtual hits. The virtual hits, i.e. ZINC000008184553, ZINC0000013641114, and ZINC000032533141, were subjected to molecular dynamics simulation studies. Compound ZINC000008184553, identified as lead, was found to have optimal stability, low toxicity under simulated conditions, and may potentially inhibit HDAC2.Communicated by Ramaswamy H. Sarma
- 12 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (9) , 4679-4698
Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach
Histone deacetylase 2 (HDAC2) is associated with various neuropathic degenerative diseases and is considered a novel target for Alzheimer's disease (AD). Elevated levels of HDAC2 trigger excitatory neurotransmission and reduce synaptic plasticity, synaptic number, and memory formation. In the current study, we identified HDAC2 inhibitors using an integrated structure and ligand-based approaches to drug design. Three pharmacophore models were generated by using different pharmacophoric features and validated using the Enrichment factor (EF), Guner-henry (GH) score, and percentage yield. The model of choice was used to screen a library of Zinc-15 compounds and interfering compounds were eliminated by using drug likeliness and PAINS filtering. Further, docking studies in three stages were carried out to obtain hits with good binding energies and were followed by ADMET studies yielding three virtual hits. The virtual hits, i.e. ZINC000008184553, ZINC0000013641114, and ZINC000032533141, were subjected to molecular dynamics simulation studies. Compound ZINC000008184553, identified as lead, was found to have optimal stability, low toxicity under simulated conditions, and may potentially inhibit HDAC2.Communicated by Ramaswamy H. Sarma
- 21 December 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (20) , 10785-10797
Identification of potential death-associated protein kinase-1 (DAPK1) inhibitors by an integrated ligand-based and structure-based computational drug design approach
- 21 December 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (20) , 10785-10797
Identification of potential death-associated protein kinase-1 (DAPK1) inhibitors by an integrated ligand-based and structure-based computational drug design approach
- 21 July 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (13) , 6089-6103
Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulations study for the identification of LIM kinase-1 inhibitors
LIM kinases (LIMKs) are a family of protein kinases involved in the regulation of actin dynamics. There are two isoforms of LIMKs i.e., LIMK1 and LIMK2. LIMK1 is expressed abundantly in neuronal tissues. LIMK1 plays an essential role in the degradation of dendritic spines, which are important for our higher brain functions, such as memory and learning. The inhibition of LIMK1 improves the size and density of dendritic spines and acts as a protective effect against Alzheimer's disease. In this study, we have adopted ligand-based drug design and molecular modelling methods to identify virtual hits. The pharmacophoric features of PF-00477736 were used to screen the Zinc15 compounds library. The identified hits were then passed through drug-likeliness and PAINS filters. Further, comprehensive docking and rigorous molecular dynamics simulation study afforded three virtual hits viz., ZINC504485634, ZINC16940431 and ZINC1091071. The hits showed a better docking score than the standard ligand, PF-00477736. The docking score was found to be –8.85, –7.50 and –7.68 kcal/mol. These hits exhibited optimal binding properties with the target in docking study, blood-brain barrier permeability, in silico pharmacokinetics and low predicted toxicity. Communicated by Ramaswamy H. Sarma Graphical Abstract
- 21 July 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (13) , 6089-6103
Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulations study for the identification of LIM kinase-1 inhibitors
LIM kinases (LIMKs) are a family of protein kinases involved in the regulation of actin dynamics. There are two isoforms of LIMKs i.e., LIMK1 and LIMK2. LIMK1 is expressed abundantly in neuronal tissues. LIMK1 plays an essential role in the degradation of dendritic spines, which are important for our higher brain functions, such as memory and learning. The inhibition of LIMK1 improves the size and density of dendritic spines and acts as a protective effect against Alzheimer's disease. In this study, we have adopted ligand-based drug design and molecular modelling methods to identify virtual hits. The pharmacophoric features of PF-00477736 were used to screen the Zinc15 compounds library. The identified hits were then passed through drug-likeliness and PAINS filters. Further, comprehensive docking and rigorous molecular dynamics simulation study afforded three virtual hits viz., ZINC504485634, ZINC16940431 and ZINC1091071. The hits showed a better docking score than the standard ligand, PF-00477736. The docking score was found to be –8.85, –7.50 and –7.68 kcal/mol. These hits exhibited optimal binding properties with the target in docking study, blood-brain barrier permeability, in silico pharmacokinetics and low predicted toxicity. Communicated by Ramaswamy H. Sarma Graphical Abstract
- 16 June 2022
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 14 (14) , 1049-1070
Identification of Sulfonamide-Based Butyrylcholinesterase Inhibitors Using Machine Learning
Aim: This study reports the designing of BChE inhibitors through machine learning (ML), followed by in silico and in vitro evaluations. Methodology: ML technique was used to predict the virtual hit... Graphical abstract Workflow for the development of BChE inhibitors.
- 16 June 2022
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 14 (14) , 1049-1070
Identification of Sulfonamide-Based Butyrylcholinesterase Inhibitors Using Machine Learning
Aim: This study reports the designing of BChE inhibitors through machine learning (ML), followed by in silico and in vitro evaluations. Methodology: ML technique was used to predict the virtual hit... Graphical abstract Workflow for the development of BChE inhibitors.
- 30 September 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 98 (6) , 1079-1097
Classification of beta‐site amyloid precursor protein cleaving enzyme 1 inhibitors by using machine learning methods
The beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) is a transmembrane aspartyl‐protease, that cleaves amyloid precursor protein (APP) at the β‐site. The sequential proteolytic cleavage of APP, first by β‐secretase and then by γ‐secretase complex, leads to the production and release of amyloid‐β peptide, a pathological hallmark of Alzheimer's disease (AD). BACE1 inhibitors are reported to possess considerable potential in decreasing the level of amyloid‐β in brain and preventing the progression of AD. A classification study has been conducted on 3536 diverse BACE1 inhibitors, obtained from Binding DB database, by extracting two types of descriptors, that is molecular property (Mordred) and fingerprints (Pubchem, MACCS and KRFP). Furthermore, based on the descriptors, various machine learning algorithms such as Naïve Bayesian (NB), nearest known neighbours (kNN), support vector machine (SVM), random forest (RF) and gradient‐boosted algorithms (XGB) were applied to develop classification models. The performance of models was evaluated by using accuracy, precision, recall and F1 score of test set. The best NB, kNN, SVM, RF and XGB classifiers had F1 score of 0.74, 0.85, 0.86, 0.87 and 0.87, respectively. The diverse 3536 BACE1 inhibitors were clustered into 11 subsets, and the structural features of each subset were evaluated. The important fragments present in active and inactive compounds were also identified. The model developed in the study would serve as a valuable tool for the designing of BACE1 inhibitors, and also in virtual screening of molecules to identify these.
- 30 September 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 98 (6) , 1079-1097
Classification of beta‐site amyloid precursor protein cleaving enzyme 1 inhibitors by using machine learning methods
The beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) is a transmembrane aspartyl‐protease, that cleaves amyloid precursor protein (APP) at the β‐site. The sequential proteolytic cleavage of APP, first by β‐secretase and then by γ‐secretase complex, leads to the production and release of amyloid‐β peptide, a pathological hallmark of Alzheimer's disease (AD). BACE1 inhibitors are reported to possess considerable potential in decreasing the level of amyloid‐β in brain and preventing the progression of AD. A classification study has been conducted on 3536 diverse BACE1 inhibitors, obtained from Binding DB database, by extracting two types of descriptors, that is molecular property (Mordred) and fingerprints (Pubchem, MACCS and KRFP). Furthermore, based on the descriptors, various machine learning algorithms such as Naïve Bayesian (NB), nearest known neighbours (kNN), support vector machine (SVM), random forest (RF) and gradient‐boosted algorithms (XGB) were applied to develop classification models. The performance of models was evaluated by using accuracy, precision, recall and F1 score of test set. The best NB, kNN, SVM, RF and XGB classifiers had F1 score of 0.74, 0.85, 0.86, 0.87 and 0.87, respectively. The diverse 3536 BACE1 inhibitors were clustered into 11 subsets, and the structural features of each subset were evaluated. The important fragments present in active and inactive compounds were also identified. The model developed in the study would serve as a valuable tool for the designing of BACE1 inhibitors, and also in virtual screening of molecules to identify these.
- 27 July 2020
- Published by Taylor & Francis in Molecular Simulation
- Vol. 46 (13) , 975-986
Computational binding study with α7 nicotinic acetylcholine receptor of Anvylic-3288: an allosteric modulator
Nicotinic receptors are ligand-gated ion channels, involved in the generation of action potential in post synaptic membrane and motor endplate. The α7 Nicotinic Acetylcholine Receptor (nAChR) is a class of nicotinic receptor involved in cognition. It is distributed in hippocampus, thalamus, sensory and information processing regions of the brain. The receptor is implicated in various diseases, including Alzheimer’s disease, Parkinsonism, Schizophrenia, Autism, Rett syndrome etc. Therefore, targeting the modulation of the receptor would be advantageous. Positive allosteric modulators (PAMs) potentiate the response i.e. peak current of the receptor. Type I allosteric modulator, Anvylic-3288 (AVL-3288), increases peak current without altering the response of α7-nAChR upon acetylcholine binding. In present study, in silico approach was used to identify the plausible binding model of AVL-3288 involved in modulation. Docking study displayed that a1 binding modes had better binding energies than the t1 and v1 modes. The MD (Molecular Dynamics) simulation produced stable complex for a1 pose, binding to agonist subpocket, with α7-nAChR having protein and ligand RMSD (Root Mean Square Deviation) in the acceptable limits, and comparable to MM/PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) results.
- 27 July 2020
- Published by Taylor & Francis in Molecular Simulation
- Vol. 46 (13) , 975-986
Computational binding study with α7 nicotinic acetylcholine receptor of Anvylic-3288: an allosteric modulator
Nicotinic receptors are ligand-gated ion channels, involved in the generation of action potential in post synaptic membrane and motor endplate. The α7 Nicotinic Acetylcholine Receptor (nAChR) is a class of nicotinic receptor involved in cognition. It is distributed in hippocampus, thalamus, sensory and information processing regions of the brain. The receptor is implicated in various diseases, including Alzheimer’s disease, Parkinsonism, Schizophrenia, Autism, Rett syndrome etc. Therefore, targeting the modulation of the receptor would be advantageous. Positive allosteric modulators (PAMs) potentiate the response i.e. peak current of the receptor. Type I allosteric modulator, Anvylic-3288 (AVL-3288), increases peak current without altering the response of α7-nAChR upon acetylcholine binding. In present study, in silico approach was used to identify the plausible binding model of AVL-3288 involved in modulation. Docking study displayed that a1 binding modes had better binding energies than the t1 and v1 modes. The MD (Molecular Dynamics) simulation produced stable complex for a1 pose, binding to agonist subpocket, with α7-nAChR having protein and ligand RMSD (Root Mean Square Deviation) in the acceptable limits, and comparable to MM/PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) results.
- 27 October 2019
- Published by Taylor & Francis in Molecular Simulation
- Vol. 46 (3) , 169-185
Structure-based screening and molecular dynamics simulation studies for the identification of potential acetylcholinesterase inhibitors
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease characterised by the appearance of amyloid β plaques and neurofibrillary tangles in the brain. The loss of cholinergic neurons is considered to be one of the contributing factors for cognitive and memory deficits in the disease. Donepezil, the most successful and prescribed drug to treat the symptoms of AD, is acetylcholinesterase (AChE) inhibitor that improves the memory and brain’s cognitive functions. In this study, the pharmacophoric features of donepezil were mapped from its cocrystal with AChE and were used to screen the Zinc15 database. The obtained hits were subjected to molecular properties and PAINS filter. The homology modelling and molecular dynamics (MD) were performed to prepare selected AChE protein model (PDB id 4EY7) for advanced studies. The virtual screening and precision docking led to the identification of five compounds. The ADMET property prediction and free energy calculations were carried out to obtain three final compounds. The Alanine scanning and MD study of the compounds viz. ZINC000013719534, ZINC000035551243 and ZINC000035596918 produced stable complexes of the ligands. The identified virtual leads have the potential for better AChE inhibition. Highlights
- 27 October 2019
- Published by Taylor & Francis in Molecular Simulation
- Vol. 46 (3) , 169-185
Structure-based screening and molecular dynamics simulation studies for the identification of potential acetylcholinesterase inhibitors
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease characterised by the appearance of amyloid β plaques and neurofibrillary tangles in the brain. The loss of cholinergic neurons is considered to be one of the contributing factors for cognitive and memory deficits in the disease. Donepezil, the most successful and prescribed drug to treat the symptoms of AD, is acetylcholinesterase (AChE) inhibitor that improves the memory and brain’s cognitive functions. In this study, the pharmacophoric features of donepezil were mapped from its cocrystal with AChE and were used to screen the Zinc15 database. The obtained hits were subjected to molecular properties and PAINS filter. The homology modelling and molecular dynamics (MD) were performed to prepare selected AChE protein model (PDB id 4EY7) for advanced studies. The virtual screening and precision docking led to the identification of five compounds. The ADMET property prediction and free energy calculations were carried out to obtain three final compounds. The Alanine scanning and MD study of the compounds viz. ZINC000013719534, ZINC000035551243 and ZINC000035596918 produced stable complexes of the ligands. The identified virtual leads have the potential for better AChE inhibition. Highlights